SEQUENCE LISTING

<110> Hermeling, Ronald
Hoffmann, James
Narasimhan, Chakravarthy

<120> GLUCAGON-LIKE PEPTIDE-1 CRYSTALS

<130> X-10242

<140> PCT/US98/26480
<141> 1998-12-14

<160> 7

<170> PatentIn version 3.0

<210> 1
<211> 31
<212> PRT
<213> Homo sapiens

<400> 1

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
20 25 30

<210> 2
<211> 31
<212> PRT
<213> Artificial/Unknown

<220>
<221> VARIANT
<222> (1)..(1)
<223> Xaa at position 1 is L-histidine, D-histidine, desamino-histidine
,

<220>
<221> VARIANT
<222> (2)..(2)
<223> Xaa at position 2 is Ala, Gly, Val, Thr, Met, Ile, and alpha-meth
y

<220>
<221> VARIANT
<222> (15)..(15)
<223> Xaa at position 15 is Glu, Gln, Ala, Thr, Ser, and Gly

<220>
<221> VARIANT
<222> (21)..(21)
<223> Xaa at position 21 is Glu, Gln, Ala, Thr, Ser, and Gly

<220>
<221> VARIANT
<222> (31)..(31)
<223> Xaa at position 31 is NH2 and Gly-OH

<400> 2

Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Xaa Gly
1 5 10 15

Gln Ala Ala Lys Xaa Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa
20 25 30

<210> 3
<211> 29
<212> PRT
<213> Artificial/Unknown

<220>
<221> VARIANT
<222> (28)..(28)
<223> Xaa at position 28 is Lys or absent

<220>
<221> VARIANT
<222> (29)..(29)
<223> Xaa at position 29 is Gly or absent;and, if Xaa at position 28 is

<400> 3

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Xaa Xaa
20 25

<210> 4
<211> 31
<212> PRT
<213> Artificial/Unknown

<220>
<221> VARIANT
<222> (1)..(1)
<223> Xaa at position 1 is 4-imidazopropionyl, 4-imidazoacetyl, or 4-im
i

<220>
<221> VARIANT
<222> (20)..(20)
<223> Xaa at position 20 is Lys or Arg

<220>
<221> VARIANT
<222> (31)..(31)
<223> Xaa at position 31 is Gly-OH or NH2

<400> 4

Xaa Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa
20 25 30

<210> 5
<211> 31
<212> PRT
<213> Artificial/Unknown

<220>
<221> VARIANT
<222> (2)..(2)
<223> Xaa at position 2 is Val

<400> 5

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
20 25 30

<210> 6
<211> 29
<212> PRT
<213> Artificial/Unknown

<220>
<221> VARIANT
<222> (13)..(13)
<223> Xaa at position 13 is Glu, Gln, Ala, Thr, Ser or Gly

<220>
<221> VARIANT
<222> (19)..(19)
<223> Xaa at position 19 is Glu, Gln, Ala, Thr, Ser or Gly

<220>
<221> VARIANT
<222> (29)..(29)
<223> Xaa at position 29 is Gly or absent

<400> 6

Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Xaa Gly Gln Ala
1 5 10 15

Ala Lys Xaa Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa
20 25

<210> 7
<211> 30
<212> PRT
<213> Artificial/Unknown

<220>
<221> VARIANT
<222> (19)..(19)
<223> Xaa at position 19 is Lys or Arg

<220>
<221> VARIANT
<222> (30)..(30)
<223> Xaa at position 30 is Gly or is absent; and Lys at position 27 ma
y

<400> 7

Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln
1 5 10 15

Ala Ala Xaa Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa
20 25 30